Display Settings:

Format

Send to:

Choose Destination
    Vaccine. 2009 Aug 27;27(39):5402-10. Epub 2009 Jul 8.

    Potential population health outcomes and expenditures of HIV vaccination strategies in the United States.

    Source

    School of Management, Yale University, New Haven, CT, United States. elisa.long@yale.edu

    Abstract

    Estimating the potential health benefits and expenditures of a partially effective HIV vaccine is an important consideration in the debate about whether HIV vaccine research should continue. We developed an epidemic model to estimate HIV prevalence, new infections, and the cost-effectiveness of vaccination strategies in the U.S. Vaccines with modest efficacy could prevent 300,000-700,000 HIV infections and save $30 billion in healthcare expenditures over 20 years. Targeted vaccination of high-risk individuals is economically efficient, but difficulty in reaching these groups may mitigate these benefits. Universal vaccination is cost-effective for vaccines with 50% efficacy and price similar to other infectious disease vaccines.

    PMID:
    19591796
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2757634
    Free PMC Article

    Images from this publication.See all images (3) Free text

    Figure 1
    Figure 3
    Figure 2

      Supplemental Content

      Icon for Elsevier Science Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk